A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1

被引：0
|
作者：
Oh, D-Y. [1 ]
Chen, L-T. [2 ]
He, A. R. [3 ]
Okusaka, T. [4 ]
Qin, S. [5 ]
Chin, S. [6 ]
Rokutanda, N. [6 ]
Uchinda, H. [7 ]
Vogel, A. [8 ]
Valle, J. W. [9 ]
Kim, H. [7 ]
机构：
[1] Seoul Natl Univ Hosp, Internal Med, Seoul, South Korea
[2] Natl Inst Canc Res, Natl Hlth Res Inst, Tainan, Taiwan
[3] Georgetown Univ, Med Ctr, Div Hematol & Oncol, Washington, DC 20007 USA
[4] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan
[5] Peoples Liberat Army, Ctr Canc, Med Oncol, Nanjing, Jiangsu, Peoples R China
[6] AstraZeneca, Oncol, Gaithersburg, MD USA
[7] AstraZeneca KK, R&D, TA Div, Med Sci Dept Oncol, Osaka, Japan
[8] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[9] Univ Manchester, Christie NHS Fdn Trust, Inst Canc Sci, Med Oncol, Manchester, Lancs, England
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
831TiP
引用
收藏
页码：319 / 319
页数：1
相关论文
共 50 条
  • [31] AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC)
    Kang, Y.
    Ohtsu, A.
    Van Cutsem, E.
    Rha, S. Y.
    Sawaki, A.
    Park, S.
    Lim, H.
    Wu, J.
    Langer, B.
    Shah, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [32] Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the Phase 3 TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in advanced biliary tract cancer (BTC)
    Koenig, Alexander-Otto
    Antonuzzo, Lorenzo
    Takahashi, Hidenori
    Park, Joon Oh
    Sookprasert, Aumkhae
    Gillmore, Roopinder
    Yang, Shengshun
    Cundom, Juan
    Petrova, Mila
    Vaccaro, Gina
    Holmblad, Marielle
    Xiong, Julia
    Heider, Katrin
    Rokutanda, Nana
    Oh, Do-Youn
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 69 - 69
  • [33] ABC-03: A randomized, phase II/III study of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine for patients with advanced biliary tract cancers
    Valle, J. W.
    Bridgewater, J. A.
    Roughton, M.
    Dive, C.
    Hughes, S.
    Wasan, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers
    Tan, Elaine S.
    Cao, Biwei
    Kim, Jongphil
    Al-Toubah, Taymeyah E.
    Mehta, Rutika
    Centeno, Barbara A.
    Kim, Richard D.
    CANCER, 2021, 127 (08) : 1293 - 1300
  • [35] A phase II/III, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer
    Oh, D-Y.
    de Braud, F.
    Bridgewater, J.
    Furuse, J.
    Hsu, C-H.
    Ikeda, M.
    Javle, M.
    Moehler, M.
    Park, J. O.
    Shen, L.
    Yoo, C.
    Helwig, C.
    Osada, M.
    Borad, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S271 - S272
  • [36] BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer.
    Goncalves, A.
    Viret, F.
    Francois, E.
    Dahan, L.
    Perrier, H.
    Lamy, R.
    Re, D.
    Largillier, R.
    Gasmi, M.
    Tchiknavorian, X.
    Turrini, O.
    Moureau-Zabotto, L.
    Delpero, J.
    Viens, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
    Zhu, Andrew X.
    Rosmorduc, Olivier
    Evans, T. R. Jeffry
    Ross, Paul J.
    Santoro, Armando
    Carrilho, Flair Jose
    Bruix, Jordi
    Qin, Shukui
    Thuluvath, Paul J.
    Llovet, Josep M.
    Leberre, Marie-Aude
    Jensen, Markus
    Meinhardt, Gerold
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) : 559 - 566
  • [38] Subsequent anticancer therapy (SAT) analysis from 3-year follow-up of the phase III TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in biliary tract cancer (BTC)
    Vogel, A.
    Oh, D-Y.
    He, A. R.
    Qin, S.
    Chen, L-T.
    Okusaka, T.
    Kim, J. W.
    Suksombooncharoen, T.
    Lee, M. A.
    Kitano, M.
    Burris, H. A.
    Bouattour, M.
    Tanasanvimon, S.
    Zaucha, R. E.
    Avallone, A.
    Cundom, J. E.
    Kuzko, A.
    Wang, J.
    Xynos, I.
    Valle, J. W.
    ANNALS OF ONCOLOGY, 2024, 35 : S233 - S234
  • [39] Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 401, pg 1853, 2023)
    Kelley, Rk
    Ueno, M.
    Yoo, C.
    LANCET, 2023, 402 (10406): : 964 - 964
  • [40] Cisplatin and gemcitabine plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase 2 trial
    Valle, J. W.
    Bousmans, N.
    Zhang, W.
    Walgren, R. A.
    Vogel, A.
    ANNALS OF ONCOLOGY, 2016, 27 : vi240
12345